Post Views: 1,854

BioRestorative Therapies Inc (OTCMKTS: BRTXQ) is easily among the most exciting stocks in small caps quickly attracting legions of penny stocks speculators and emerging as a volume leader in small caps. Q stocks are notoriously volatile and have been some of the biggest runners in small caps history.

BioRestorative filed for bankruptcy protection in March but has partnered on a new bankruptcy reorganization plan with one of its creditors Auctus Capital in which the Company would emerge from bankruptcy with the commons intact, ready to begin their phase 2 trials and get BioRestorative back on a national stock exchange. On September 10th, a hearing was held for confirmation of the bankruptcy reorganization plan submitted jointly by the company and Auctus Capital Partners. Based on notes in Pacer, the plan has been confirmed, judges order pending, but expected soon, likely the week of September 14, 2020.

BioRestorative Therapies Inc (OTCMKTS: BRTXQ) operating out of Melvile, New York is a life sciences company focused on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The Company was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions. BioRestorative Therapies advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies own regenerative potential to treat major diseases more effectively than current interventions. Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both chronic back pain caused by disc degeneration, as well as metabolic disorders including obesity and diabetes. BioRestorative Therapies lead cell therapy candidate, BRTX-100 is a novel product to treat damaged, degenerating discs, and is anticipated to be safer, cheaper, and more effective upon a single treatment. Specifically, BRTX-100 is an autologous stem cell product that uses your own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. The Company has received authorization from the FDA to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

The Company is also developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells, or BADSC, to generate brown adipose tissue, or BAT. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning, as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

To Find out the inside Scoop on BioRestorative Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BioRestorative owns a valuable intelectual property portfolio including unique international Stem Cell patents as well as 8 patents issued, in the United States and other countries, for the Companys brown fat technology related to BioRestoratives metabolic program (ThermoStem Program).

On March 20 BioRestorative filed a voluntary petition commencing a case under chapter 11 of title 11 of the U.S. Code in the United States Bankruptcy Court for the Eastern District of New York. The Companys chapter 11 case is being administered under the caption, In re: BioRestorative Therapies, Inc., Case No. 8-20-71757.

Initially intellectual property lawyer John Desmarais entered into a stalking horse agreement to buy the company. He would pay $500,000 to acquire the company, along with their assets (including the intellectual property). The deal with Desmarais fell apart in July when Auctus Capital partnered with the Company on a new bankruptcy reorganization plan in which the Company would emerge from bankruptcy with the commons intact, ready to begin their phase 2 trials and get BioRestorative back on a national stock exchange. On September 10th, a hearing was held for confirmation of the bankruptcy reorganization plan submitted jointly by the company and Auctus Capital Partners. Based on notes in Pacer, the plan has been confirmed, judges order pending, but expected soon, likely the week of September 14, 2020. Further detail will be added upon review of the judges order, but the plan and disclosure statement are available to Pacer or Pacermonitor subscribers.

We have a Monster Pick Coming. Subscribe Right Now!

Currently running northbound in a hurry BioRestorative is an exciting story developing in small caps; BioRestorative filed for bankruptcy protection in March but has partnered on a new bankruptcy reorganization plan with one of its creditors Auctus Capital in which the Company would emerge from bankruptcy with the commons intact, ready to begin their phase 2 trials and get BioRestorative back on a national stock exchange. On September 10th, a hearing was held for confirmation of the bankruptcy reorganization plan submitted jointly by the company and Auctus Capital Partners. Based on notes in Pacer, the plan has been confirmed, judges order pending, but expected soon, likely the week of September 14, 2020. BioRestorative owns a valuable intelectual property portfolio including unique international Stem Cell patents as well as 8 patents issued, in the United States and other countries, for the Companys brown fat technology related to BioRestoratives metabolic program (ThermoStem Program). We will be updating on BioRestorative when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with BioRestorative.

Disclosure: we hold no position in BRTXQ either long or short and we have not been compensated for this article.

Share.

Here is the original post:
The Fascinating Story of Q Stock BioRestorative Therapies Inc (OTCMKTS: BRTXQ) - MicroCap Daily